Aptevo Therapeutics Inc. — Investor Relations & Filings
Filings indexed
683
across all filing types
Latest filing
2026-05-06
Regulatory Filings
Country
US
United States of America
Listing
US
APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | |
| Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | |
| 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 8-K Filing | 2026-02-03 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 42001589 | 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | ||
| 33062838 | Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | ||
| 32896295 | 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | ||
| 31224528 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224515 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224508 | 8-K Filing | 2026-02-03 | English | ||
| 31224455 | 424B4 Filing | 2026-01-30 | English | ||
| 31224522 | S-1 Filing | 2026-01-28 | English | ||
| 31224517 | DEF 14A Filing | 2026-01-26 | English | ||
| 12947011 | PRE 14A | 2026-01-16 | English | ||
| 12947014 | 8-K | 2026-01-09 | English | ||
|
2025
4 filings
| |||||
| 12947015 | 8-K | 2025-12-29 | English | ||
| 12947016 | 8-K | 2025-12-09 | English | ||
| 12947017 | Regulatory Filings 2025 | 2025-11-26 | English | ||
| 12947019 | 424B4 | 2025-11-25 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AIM ImmunoTech Inc.
Immuno-pharma company developing therapeutics for oncology,…
|
AIM | US | Professional, scientific and te… |
|
Ainos, Inc.
Develops AI-driven diagnostics, immune therapeutics, and te…
|
AIMD | US | Professional, scientific and te… |
|
Akela Pharma Inc.
Integrated drug developer focused on pain and inhalation, p…
|
— | CA | Professional, scientific and te… |
|
Akero Therapeutics, Inc.
Clinical-stage company developing treatments for serious me…
|
AKRO | US | Professional, scientific and te… |
|
Aladdin Healthcare Technologies SE
Develops AI-powered tools for drug discovery and diagnostic…
|
NMI | DE | Professional, scientific and te… |
|
Alamar Biosciences, Inc.
Powering precision proteomics for earliest disease detectio…
|
ALMR | US | Professional, scientific and te… |
|
Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cel…
|
TCRT | US | Professional, scientific and te… |
|
ALGORAE PHARMACEUTICALS LIMITED
Biopharmaceutical firm using AI to develop neurodegenerativ…
|
1AI | AU | Professional, scientific and te… |
|
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing thera…
|
ALGS | US | Professional, scientific and te… |
|
Allelix Biopharmaceuticals Inc.
Biopharmaceutical R&D focused on protein-based drugs and ne…
|
ALX | CA | Professional, scientific and te… |
Aptevo Therapeutics Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35422/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35422 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35422 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35422 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35422}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aptevo Therapeutics Inc. (id: 35422)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.